NasdaqCM - Nasdaq Real Time Price USD

Bluejay Diagnostics, Inc. (BJDX)

1.9100

-0.0200

(-1.04%)

At close: 4:00:01 PM EDT

2.0565

+0.15

+(7.67%)

After hours: 5:13:43 PM EDT

Bluejay Announces Abstract Accepted for Presentation at the 2025 Society of Academic Emergency Medicine (SAEM) Annual Meeting

New clinical data from the SYMON-I study to evaluate IL-6 in sepsis patients to be presented.ACTON, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX), today announced acceptance of an abstract related to the Symphony IL-6 Test, the company’s lead product candidate, for presentation at the Society of Academic Emergency Medicine (SAEM) Annual Meeting, taking place in Philadelphia May 13-16, 2025. Results from SYMON-I, a pilot clinical study of interleukin-6 (IL-6)

GlobeNewswire last month

BJDX
-1.04%
Bluejay Diagnostics Announces Entry into Warrant Inducement Transaction for Approximately $3.7 Million in Gross Proceeds

ACTON, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced that it has entered into an agreement with institutional investors that are existing holders of warrants to purchase shares of common stock of the Company for cash (the “Existing Warrants”), wherein the investors agreed to exe

GlobeNewswire last month

BJDX
-1.04%
Bluejay Diagnostics Announces Reverse Stock Split

ACTON, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced that the Company’s Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1-for-50 (the “Reverse Stock Split”). The Reverse Stock Split will become effective at 12:01 a.m. Eastern Time

GlobeNewswire 6 months ago

BJDX
-1.04%
Bluejay Diagnostics Announces Closing of $8.75 Million Underwritten Public Offering

ACTON, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced the closing of a firm commitment underwritten public offering with gross proceeds to the Company expected to be approximately $8.75 million, before deducting underwriting discounts and other estimated expenses payable by the Co

GlobeNewswire 10 months ago

BJDX
-1.04%
Top Midday Decliners

Top Midday Decliners

PREMIUM
MT Newswires 10 months ago

BJDX
-1.04%

TNXP
Bluejay Diagnostics Announces Pricing of $8.75 Million Underwritten Public Offering

ACTON, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced the pricing of a firm commitment underwritten public offering with gross proceeds to the Company expected to be approximately $8.75 million, before deducting underwriting discounts and other estimated expenses payable by the Co

GlobeNewswire 10 months ago

BJDX
-1.04%
SYMON-I Study of Symphony IL-6 Suggests Prediction of Mortality in Sepsis Patients

Results from primary analysis of the SYMON-I pilot clinical study consistent with IL-6 as a predictor of patients who have a mortality event with 28 days after sepsis and septic shock diagnosis and are admitted to the intensive care unit (ICU).ACTON, Mass., June 26, 2024 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX), today announced results from the primary analysis of SYMON-I, a multicenter pilot clinical study investigating the role of interleukin-6 (IL-6) in patients diagnosed

GlobeNewswire 10 months ago

BJDX
-1.04%
BJDX: 1Q:24 Financial Update

By John Vandermosten, CFA NASDAQ:BJDX Bluejay Diagnostics, Inc. (NASDAQ:BJDX) reported first quarter 2024 operational and financial results in a Form 10-Q on May 15th, 2024. Pilot study SYMON-I is underway and has completed enrollment, with 143 subjects entering the trial. Based on the recruitment information in SYMON-I’s clincaltrials.gov entry and management commentary, we expect the final data

Zacks Small Cap Research 11 months ago

BJDX
-1.04%

Performance Overview

Return	BJDX	S&P 500 (^GSPC)
YTD	-60.78%	+1.00%
1-Year	-99.12%	+11.91%
3-Year	-99.98%	+52.27%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Bluejay Diagnostics, Inc. (BJDX)

Bluejay Announces Abstract Accepted for Presentation at the 2025 Society of Academic Emergency Medicine (SAEM) Annual Meeting

Bluejay Diagnostics Announces Entry into Warrant Inducement Transaction for Approximately $3.7 Million in Gross Proceeds

Bluejay Diagnostics Announces Reverse Stock Split

Bluejay Diagnostics Announces Closing of $8.75 Million Underwritten Public Offering

Top Midday Decliners

Bluejay Diagnostics Announces Pricing of $8.75 Million Underwritten Public Offering

SYMON-I Study of Symphony IL-6 Suggests Prediction of Mortality in Sepsis Patients

BJDX: 1Q:24 Financial Update

Performance Overview